Tesaro rock­ets up af­ter PARP in­hibitor aces PhI­II study and R&D ri­val­ry in­ten­si­fies

Tesaro’s close­ly-watched PARP in­hibitor ni­ra­parib has aced its first Phase III chal­lenge, rack­ing up a slate of promis­ing out­comes for pro­gres­sion-free sur­vival for ad­vanced, re­cur­ring ovar­i­an can­cer that will take it straight to the FDA — which has al­ready ap­proved a ri­val with much worse da­ta.

“This is the first ran­dom­ized Phase III of a PARP in­hibitor to be suc­cess­ful,” says Mary Lynne Hed­ley, the pres­i­dent and COO of Waltham, MA-based Tesaro ($TSRO).

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.